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Acute Effects of Statins*
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In addition to lowering low-density lipoprotein cholesterol,
statins improve vascular function by cholesterol-independent
effects in experimental models. These extrahepatic effects are
often called “pleiotropic”; however, specific underlying molec-
ular mechanisms have been identified in animal and cell culture
studies. They relate to the inhibition of isoprenylation of small
G proteins. Inhibition of 3-hydroxy-3-methylglutaryl coen-
zyme A (HMG-CoA) reductase blocks the synthesis of iso-
prenoids, which are upstream of cholesterol (1,2). Therefore,
statins inhibit isoprenoid and cholesterol synthesis at the same
time, making it difficult to assess the relative contribution of
the 2 for the reduction of vascular events. One could speculate
that their importance may depend on the clinical situation.
There is no doubt regarding the long-term importance of
low-density lipoprotein cholesterol for atherogenesis. The
isoprenoid-dependent effects (Fig. 1), however, may be espe-
cially important for the acute effects of statin treatment.
See page 60
In their elegant paper in this issue of the Journal,
Antoniades et al. (3) provide new mechanistic insight into
the underlying mechanisms of acute statin effects. They
found that statins rapidly prevent oxidative stress (superox-
ide anion [O2
] and peroxynitrite [ONOO]) in samples
f the right atrial appendage through inhibition of Rac1
soprenylation and subsequent inhibition of nicotinamide
denine dinucleotide phosphate (NADPH) oxidase. The
2
 and ONOO in the atrial myocardium from 303
patients undergoing cardiac surgery were associated with
increased risk of atrial fibrillation, the need for post-
operative inotropic support, and the length of hospital stay
after surgery. They confirmed these data in a small prospec-
tive study (n  42) showing that preoperative atorvastatin
treatment suppressed atrial NADPH oxidase activity and
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 and ONOO production. Their data
xtend previous findings that showed that prospective short-
erm oral statin treatment of patients with ischemic heart
isease is able to down-regulate Rac1 activation and
uperoxide-producing NADPH oxidase activity in the right
trium (4,5).
In a parallel publication, Antoniades et al. (6) show a
apid beneficial regulation of vascular nitric oxide (NO)
ioavailability and reduced O2
 in samples of the internal
ammary arteries. Statins increased vascular tetrahydrobi-
pterin bioavailability by up-regulating GTP-cyclohydrolase I,
esulting in improved endothelial NO synthase coupling
nd reduced vascular O2
 (6). This mechanism adds addi-
ional information on the rapid up-regulation of endothelial
O production by statins (7).
As all good studies, this paper and the reports of other
uthors on acute statin effects raise further questions such as
he details of the signaling and the exact time course of the
holesterol-independent events. If the very rapid effects are
ediated by inhibition of isoprenylation, as proposed, the
ells have to be very rapidly depleted of isoprenoids and
soprenylated proteins by the statin treatment. To under-
tand this observation, the kinetics of isoprenoid turnover in
ifferent cell types and cellular compartments would be of
nterest. Similarly, intracellular statin concentrations and
inetics are poorly understood. Are specific drug transport-
rs important? Do lipophilic statins differ from more hy-
rophilic drugs with regard to acute effects because of their
ery different serum concentrations? There are no convinc-
ng clinical data supporting this assumption. An (unproven)
xplanation could be that cholesterol-independent effects
ould be mediated by inhibition of HMG-CoA reductase in
he cardiovascular cell or in the liver with inhibition of
epatic mevalonate synthesis, resulting in secondary sys-
emic isoprenoid depletion in peripheral cells. If that is the
Figure 1 Pathways Acutely Affected by Statin Treatment
CoA  coenzyme A; eNOS  endothelial nitric oxide synthase; HMG  3-hydroxy-3-
methylglutaryl; NAD(P)H-ox  nicotinamide adenine dinucleotide phosphate oxi-
dase; PP  pyrophosphate.
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vascular effects within hours? These fundamental questions
are not all new but still await complete answers.
Furthermore, in light of the accumulated mechanistic
data, the most important future issue from the perspective
of patient care is the relevance of the rapid statin effects for
clinical endpoints. Indeed, it seems to be time to move to
definitive prospective clinical trials testing acute effects of
statins.
To study the acute effects of statins, oral application may
not be sufficient, but an intravenous formulation, which is
not available at the moment, could be helpful. Potential
patient groups who may benefit from the proposed intrave-
nous statins are shown in Table 1. They include patients
ith acute coronary syndromes for whom high-dose oral
tatin therapy was shown to be beneficial and “re-loading”
or percutaneous coronary interventions improved outcomes
8,9). A single oral dose of statin was shown to improve
ndothelium-dependent coronary vasomotion after 24 h in
he absence of significant cholesterol reduction (10). More-
ver, statins rapidly improved endothelial vasodilation and
ecreased serum markers of oxidative stress and inflamma-
ion independent of cholesterol lowering in patients with
ormal low-density lipoprotein cholesterol (11). Further-
ore, patients with ischemic strokes appear to benefit from
arly statin treatment (12,13). The effectiveness of an
ntravenous statin formulation was tested in a mouse model
f focal brain ischemia, in which intravenous rosuvastatin
educed lesion size when given as long as 4 h after ischemia.
ompared to intraperitoneal treatment, the intravenous
dministration extended the treatment window for ischemic
troke by 3 h (14). Recent clinical evidence points toward
educed risk of myocardial infarction and death for patients
ith vascular risk who are undergoing surgery and are
eceiving statin treatment (15). Statins have been shown to
revent atrial fibrillation in situations of risk such as surgery
y mechanisms related to inhibition of small G protein
soprenylation (16,17).
Conversely, these beneficial rapid effects may also become
elevant when statin treatment is stopped in patients at high
isk or situations of high risk (18). Sudden discontinuation
f statin medication may exert negative effects on patients
ith acute vascular syndromes, whereas for stable vascular
atients, discontinuation may not be a problem. The pro-
osed mechanism again relates to the isoprenoid interme-
iates of the cholesterol synthesis pathway. Withdrawal of
tatin treatment confers overshoot activation of the small
Potential Indications for the Development ofan Intrave ous Statin FormulationTable 1 Potential Indications f r the Development ofan Intravenous Statin Formulation
Acute coronary syndromes
Ischemic stroke
Perioperative, for surgery involving patients with high vascular risk
Perioperative, for surgery involving patients at risk for atrial fibrillationPatients with high vascular risk unable to take oral statinsG-proteins RhoA and Rac1, causing production of reactive
oxygen species and suppression of NO bioavailability (19).
n intravenous formulation could be helpful for all patients
t high vascular risk who are unable to take oral statins for
arious reasons (e.g., being on a ventilator), to take advan-
age of positive acute effects and to prevent withdrawal,
specially in high-risk situations such as acute coronary or
erebral ischemia and surgery.
In summary, the studies by Antoniades et al. (3,6) provide
mportant insights into the cholesterol-independent effects of
tatins on vascular and myocardial tissue. These studies are
ood examples of translational research confirming ex-vivo
bservations in human tissue and in hypothesis-generating
linical studies. As much as additional cellular studies are
ecessary to fully understand the signal transduction underly-
ng the acute effects of statins, the main challenge for the future
s to test the clinical relevance of statins by performing
rospective trials with clinical endpoints.
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